Abbreviations

Abbreviations

GMB

Adult glioblastoma

pHGG

Paediatric high-grade glioma

UNCAN

EU initiative for understanding cancer

MRI

Magnetic resonance imaging 

SOC

Standard of care

I/O

Immuno-oncology

TTF

Tumour treating fields

First annual meeting of the Understanding (tumour-host interactions) Cluster held in Barcelona

On 31 January 2025, partners from across the Understanding (tumour-host Interactions) Cluster (U-THI-Clust) gathered in Barcelona, Spain, for the first annual cluster meeting, organised by the THRIVE project at the Centre Esther Koplowitz (IDIBAPS). The meeting brought together representatives from the six cluster projects, namely ARTURO, GLIOMATCH, HIT-GLIO, MULTIR, SPACETIME and THRIVE, alongside the Project Officer from HaDEA.

Launching collaboration across the cluster

The meeting marked the starting point for structured collaboration within the U-THI-Clust under the EU Cancer Mission. Discussions focused on strengthening joint work across projects addressing tumour-host interactions, with emphasis on improving understanding of cancer development and fostering coordinated research efforts.

Each project presented its objectives and approach, highlighting complementary expertise ranging from spatial tumour analysis and immunotherapy to microbiota research and multi-omics integration. This exchange confirmed strong potential for synergies across tumour types and methodologies.

Establishing working groups and priorities

A central outcome of the meeting was to align on and coordinate joint activities, deliverables and strategic alignment across the different working groups of the cluster, which include:

  • Data Management and Sharing (led by GLIOMATCH)
  • Communication and Dissemination (led by MULTIR)
  • Research and Innovation (led by SPACETIME)
  • Addressing Inequalities (led by ARTURO and GLIOMATCH)
  • Citizen and Patient Engagement (led by HIT-GLIO)
  • Annual Meetings and Events (led by THRIVE in year one)

 

Snapshots from meeting organised by the THRIVE project

Key discussions and first conclusions

Across the different sessions, several common priorities and challenges were identified:

  • The need to harmonise data management practices and contribute to a common Data Management Plan chapter
  • Challenges related to GDPR, data sharing and material transfer agreements in multi-partner research
  • The importance of coordinated communication actions and shared dissemination materials
  • The need to address inequalities in access to research and healthcare outcomes
  • Strengthening citizen and patient engagement across projects

The meeting also emphasised the role of the UNCAN platform in supporting data sharing and collaboration at European level, alongside the expectation to develop policy recommendations based on cluster findings.

Building the foundation for future collaboration

The first annual meeting established the operational framework for the U-THI-Clust and confirmed the commitment of all partners to work collaboratively towards the objectives of the EU Cancer Mission. It also set the basis for future joint deliverables, policy inputs and coordinated research activities. A full recap of the meeting is available in the 1st ‘Understanding (tumour-host) interactions’ Cluster press release published in May 2025.

Follow GLIOMATCH on LinkedIn and Facebook for more information on brain tumour research and updates on our milestones towards improving the clinical outcomes of GBM and pHGG.

For more pictures from our events, visit our photo gallery.

More Posts

GLIOMATCH results contribute to new EIC-funded project GLIOBREAK

Results from GLIOMATCH are supporting the newly funded EIC Transition project GLIOBREAK, coordinated by Beactica Therapeutics and with the involvement of KU Leuven. The project will advance BEA-17, a first-in-class LSD1–CoREST degrader, towards clinical readiness, including IND-enabling studies and regulatory submission.

International Childhood Cancer Day 2026

On International Childhood Cancer Day, GLIOMATCH highlights the urgent need for research into paediatric high-grade gliomas (pHGGs), rare and aggressive brain tumours affecting children. With a median survival of just over one year and no curative treatment available, collaborative research efforts are essential to better understand the disease, develop dedicated models, and tailor therapies that improve outcomes and quality of life for young patients and their families.

International Day of Women and Girls in Science 2026

GLIOMATCH celebrates the women researchers across its consortium whose expertise and commitment drive the development of tailored immunotherapies for malignant brain tumours, marking the International Day of Women and Girls in Science 2026.